Learn more about our policy experts.

Media Contacts

Angela Bradbery, Director of Communications
w. (202) 588-7741
c. (202) 503-6768
abradbery@citizen.org, Twitter

Don Owens, Deputy Director of Communications
w. (202) 588-7767

Karilyn Gower, Press Officer
w. (202) 588-7779

David Rosen, Press Officer, Regulatory Affairs
w. (202) 588-7742

Nicholas Florko, Communications Officer, Global Trade Watch
w. (202) 454-5108

Other Important Links

Press Release Database
Citizen Vox blog
Texas Vox blog
Consumer Law and Policy blog
Energy Vox blog
Eyes on Trade blog

Follow us on Twitter


Feb. 26, 2014

Dozens of Groups, Experts Call on FDA to Withdraw Its Approval of Zohydro, Supercharged Opioid

A Single Dose Could Kill a Child; FDA Approved Drug Despite Overwhelming Negative Advisory Committee Vote

WASHINGTON, D.C. – More than 40 consumer organizations, health care agencies, addiction treatment providers, and community-based drug and alcohol prevention programs today called on the U.S. Food and Drug Administration (FDA) to revoke its approval of Zohydro, an opioid so powerful that a single dose could kill a child.

The FDA approved the drug in October against the advice of its own advisory committee, which voted 11-2 against allowing Zohydro, made by Zogenix and Alkermes, to be sold. It is the first single-ingredient hydrocodone drug ever to be approved. Other drugs, such as Vicodin, combine hydrocodone and acetaminophen. Zohydro is scheduled to be available in March.

Earlier this month, three U.S. senators raised concerns about the drug and asked the FDA to explain how it will prevent misuse. Writing on behalf of “groups on the front-line of the nation’s opioid addiction epidemic,” the organizations said there is no need for another high-dose opioid.

“Too many people have already become addicted to similar opioid medications and too many lives have been lost,” said Andrew Kolodny, president of Physicians for Responsible Opioid Prescribing. “The FDA should exercise its responsibility to protect the public’s health by reversing its approval of Zohydro.”

“I’m worried about their plan to market the drug for back pain and other common problems,” said Judy Rummler, chair of the FED UP! Coalition and president of the Steve Rummler Hope Foundation.  Judy’s son Steve died of a drug overdose in 2011.  He had become addicted to the painkillers that were prescribed to him for his chronic back pain.

Opioid prescriptions have skyrocketed in recent years. The U.S. has just 5 percent of the world’s population but is consuming more than 99 percent of the world’s hydrocodone. Opioid addiction and overdose deaths have increased commensurately.

“The capsules will contain a whopping dose of hydrocodone,” said Pete Jackson, president of Advocates for the Reform of Prescription Opioids. Jackson lost his 18-year-old daughter to a single dose of OxyContin. “It’s crazy to let this drug go on the market as it undoubtedly will become the next OxyContin that will fuel the opioid addiction epidemic.”

Added Dr. Michael Carome, director of Public Citizen’s Health Research Group, “I’m amazed that the FDA would approve a dangerous new opioid over the strong objection of its advisory panel. In the midst of a severe epidemic of opioid addiction and overdose deaths, this is the last thing we need.” 

The letter is available at http://www.citizen.org/hrg2185.


Copyright © 2016 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.

Public Citizen, Inc. and Public Citizen Foundation


Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.


To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.